Procognitive and neuroprotective activity of a novel α7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 2, 2009, Pages 459-468

  Roncarati, Renza ^a,c   Scali, Carla ^a   Comery, Thomas A ^b   Grauer, Steven M ^b   Aschmi, Suzan ^b   Bothmann, Hendrick ^a   Jow, Brian ^b   Kowal, Dianne ^b   Gianfriddo, Marco ^a   Kelley, Cody ^b   Zanelli, Ugo ^a   Ghiron, Chiara ^a   Haydar, Simon ^b   Dunlop, John ^b   Terstappen, Georg C ^a  

^a Siena Biotech SpA   (Italy)

^b PFIZER INC   (United States)

^c Strada del Petriccio e Belriguardo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 MORPHOLIN 4 YL PENTANOIC ACID(4 PYRIDIN 3 YL PHENYL)AMIDE; ACETYLCHOLINE; APOMORPHINE; BUNGAROTOXIN RECEPTOR; CALCIUM ION; CHOLINE ACETYLTRANSFERASE; DIZOCILPINE; METHYLLYCACONITINE; NICOTINIC AGENT; QUISQUALIC ACID; SCOPOLAMINE; SEN 12333; UNCLASSIFIED DRUG; WAY 317538; 5 MORPHOLIN 4 YLPENTANOIC ACID (4 PYRIDIN 3 YLPHENYL)AMIDE; 5-MORPHOLIN-4-YLPENTANOIC ACID (4-PYRIDIN-3-YLPHENYL)AMIDE; ALPHA-BUNGAROTOXIN RECEPTOR; CALCIUM; MORPHOLINE DERIVATIVE; NEUROPROTECTIVE AGENT; NICOTINIC RECEPTOR; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ATTENTION; CALCIUM TRANSPORT; CHOLINERGIC SYSTEM; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; EPISODIC MEMORY; HEMISPHERE; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; NERVE CELL; NEUROPROTECTION; NONHUMAN; PASSIVE AVOIDANCE; PATCH CLAMP; PERCEPTION; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WHOLE CELL; ANIMAL; ANIMAL BEHAVIOR; CELL LINE; CELL MEMBRANE POTENTIAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; LONG EVANS RAT; METABOLISM; MOTOR ACTIVITY; PROTEIN BINDING; RADIOASSAY; WISTAR RAT;

ANIMALS; BEHAVIOR, ANIMAL; CALCIUM; CELL LINE; COGNITION; COGNITION DISORDERS; HUMANS; MALE; MEMBRANE POTENTIALS; MOLECULAR STRUCTURE; MORPHOLINES; MOTOR ACTIVITY; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; NICOTINIC AGONISTS; PATCH-CLAMP TECHNIQUES; PROTEIN BINDING; PYRIDINES; RADIOLIGAND ASSAY; RATS; RATS, LONG-EVANS; RATS, WISTAR; RECEPTORS, NICOTINIC;

EID: 65649092520     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.150094     Document Type: Article

References (42)

1. Acker BA, Jacobsen EJ, Rogers BN, Wishka DG, Reitz SC, Piotrowski DW, Myers JK, Wolfe ML, Groppi VE, Thornburgh BA, et al. (2008) Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c] pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg Med Chem Lett 18:3611-3615.
2. Alkondon M, Pereira EF, Eisenberg HM, and Albuquerque EX (2000) Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J Neurosci 20:66-75.
3. Bartolini L, Casamenti F, and Pepeu G (1996) Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions. Pharmacol Biochem Behav 53:277-283.
4. Bartus RT, Dean RL 3rd, Beer B, and Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-414.
5. Boess FG, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J, Methfessel C, Riedl B, Schnizler K, van der Staay FJ, et al. (2007) The novel α7 nicotinic acetylcholine receptor agonist N[(3R)-1-azabicyclo[2.2. 2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 321:716-725.
6. Broad LM, Felthouse C, Zwart R, McPhie GI, Pearson KH, Craig PJ, Wallace L, Broadmore RJ, Boot JR, Keenan M, et al. (2002) PSAB-OFP, a selective alpha 7 nicotinic receptor agonist, is also a potent agonist of the 5-HT3 receptor. Eur J Pharmacol 452:137-144.
7. Casamenti F, Prosperi C, Scali C, Giovannelli L, and Pepeu G (1998) Morphological, biochemical and behavioural changes induced by neurotoxic and inflammatory insults to the nucleus basalis. Int J Dev Neurosci 16:705-714.
8. Counts SE, He B, Che S, Ikonomovic MD, DeKosky ST, Ginsberg SD, and Mufson EJ (2007) alpha7 Nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease. Arch Neurol 64:1771-1776.
9. Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, and Perry E (2001) Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 49:175-184.
10. De Simone R, Ajmone-Cat MA, Carnevale D, and Minghetti L (2005) Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclo-oxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflammation 2:4.
11. Dunlop J, Roncarati R, Jow B, Bothmann H, Lock T, Kowal D, Bowlby M, and Terstappen GC (2007) In vitro screening strategies for nicotinic receptor ligands. Biochem Pharmacol 74:1172-1181.
12. Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, and Brioni JD (2008) The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 154:1166-1181.
13. Fabian-Fine R, Skehel P, Errington ML, Davies HA, Sher E, Stewart MG, and Fine A (2001) Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. J Neurosci 21:7993-8003.
14. Frazier CJ, Rollins YD, Breese CR, Leonard S, Freedman R, and Dunwiddie TV (1998) Acetylcholine activates an alpha-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci 18:1187-1195.
15. Freedman R, Adams CE, and Leonard S (2000) The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanat 20:299-306.
16. Gault J, Hopkins J, Berger R, Drebing C, Logel J, Walton C, Short M, Vianzon R, Olincy A, Ross RG, et al. (2003) Comparison of polymorphisms in the alpha7 nicotinic receptor gene and its partial duplication in schizophrenic and control subjects. Am J Med Genet B Neuropsychiatr Genet 123B:39-49.
17. Gotti C and Clementi F (2004) Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74:363-396.
18. Gotti C, Zoli M, and Clementi F (2006) Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 27:482-491.
19. Hajós M, Hurst RS, Hoffmann WE, Krause M, Wall TM, Higdon NR, and Groppi VE (2005) The selective ot7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 312:1213-1222.
20. Hellström-Lindahl E, Court J, Keverne J, Svedberg M, Lee M, Marutle A, Thomas A, Perry E, Bednar I, and Nordberg A (2004) Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. Eur J Neurosci 19:2703-2710.
21. Hu M, Schurdak ME, Puttfarcken PS, El Kouhen R, Gopalakrishnan M, and Li J (2007) High content screen microscopy analysis of A beta 1-42-induced neurite outgrowth reduction in rat primary cortical neurons: neuroprotective effects of alpha 7 neuronal nicotinic acetylcholine receptor ligands. Brain Res 1151:227-235.
22. Jessen F, Kucharski C, Fries T, Papassotiropoulos A, Hoenig K, Maier W, and Heun R (2001) Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease. Am J Psychiatry 158:1319-1321.
23. Kem WR (2000) The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res 113:169-181.
24. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, and Akaike A (2001) α7 Nicotinic receptor transduces signals to phosphatidylino-sitol 3-kinase to block A β-amyloid-induced neurotoxicity. J Biol Chem 276:13541-13546.
25. Lanni C, Lenzken SC, Pascale A, Del Vecchio I, Racchi M, Pistoia F, and Govoni S (2008) Cognition enhancers between treating and doping the mind. Pharmacol Res 57:196-213.
26. Levin ED, Bettegowda C, Blosser J, and Gordon J (1999) AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol 10: 675-680.
27. Marchi M, Risso F, Viola C, Cavazzani P, and Raiteri M (2002) Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem 80:1071-1078.
28. Newhouse PA, Potter A, and Singh A (2004) Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 4:36-46.
29. O'Neill MJ, Murray TK, Lakics V, Visanji NP, and Duty S (2002) The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr Drug Targets CNS Neurol Disord 1:399-411.
30. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, et al. (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32:17-34.
31. Ren K, King MA, Liu J, Siemann J, Altman M, Meyers C, Hughes JA, and Meyer EM (2007) The alpha7 nicotinic receptor agonist 4OH-GTS-21 protects axotomized septohippocampal cholinergic neurons in wild type but not amyloid-overexpressing transgenic mice. Neuroscience 148:230-237.
32. Rezvani AH, Kholdebarin E, Brucato FH, Callahan PM, Lowe DA, and Levin ED
33. (2009) Effect of R3487/MEM3454, a novel nicotinic ot7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. Prog Neuropsychopharmacol Biol Psychiatry 33:269-275.
34. Scali C, Giovannini MG, Prosperi C, Bartolini L, and Pepeu G (1997) Tacrine administration enhances extracellular acetylcholine in vivo and restores the cognitive impairment in aged rats. Pharmacol Res 36:463-469.
35. Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, Ehrhart J, Silver AA, Sanberg PR, and Tan J (2004) Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 89:337-343.
36. Stassen HH, Bridler R, Hagele S, Hergersberg M, Mehmann B, Schinzel A, Weisbrod M, and Scharfetter C (2000) Schizophrenia and smoking: evidence for a common neurobiological basis? Am J Med Genet 96:173-177.
37. Suzuki T, Hide I, Matsubara A, Hama C, Harada K, Miyano K, Andra M, Matsuba-yashi H, Sakai N, Kohsaka S, et al. (2006) Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J Neurosci Res 83:1461-1470.
38. Teaktong T, Graham A, Court J, Perry R, Jaros E, Johnson M, Hall R, and Perry E (2003) Alzheimer's disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immun ore activity in astrocytes. Glia 41:207-211.
39. Van Kampen M, Selbach K, Schneider R, Schiegel E, Boess F, and Schreiber R (2004) AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology (Berl) 172:375-383.
40. Vannucchi MG, Scali C, Kopf SR, Pepeu G, and Casamenti F (1997) Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats. Neuroscience 79:837-846.
41. Wang H, Yu M, Ochani M, Amelia CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, et al. (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421:384-388.
42. Yu WF, Guan ZZ, Bogdanovic N, and Nordberg A (2005) High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp Neurol 192:215-225.